Common Contracts
5 similar Executive Employment Agreement contracts by Ovid Therapeutics Inc.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 8th, 2018 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Matthew During (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its President and Chief Scientific Officer (“CSO”) pursuant to the terms of an Executive Employment Agreement with the Company dated June 5, 2015 (the “Prior Agreement”). Executive and the Company hereby agree to amend and restate the Prior Agreement. The terms and conditions set forth in this AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of the effective date of the first registration statement filed by the Company to register shares of its common stock for sale to the public through one or more underwriters (the “Effective Date”), and shall supersede and replace the terms and conditions set forth in the Prior Agreement. Certain capitalized terms used in this Agreement are defined in Section 6.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 8th, 2018 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Yaron Werber (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its Chief Business and Financial Officer pursuant to the terms of an Executive Employment Agreement with the Company dated May 31, 2015 (the “Prior Agreement”). Executive and the Company hereby agree to amend and restate the Prior Agreement. The terms and conditions set forth in this AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of the effective date of the first registration statement filed by the Company to register shares of its common stock for sale to the public through one or more underwriters (the “Effective Date”), and shall supersede and replace the terms and conditions set forth in the Prior Agreement. Certain capitalized terms used in this Agreement are defined in Section 6.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • April 18th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Dirk Haasner (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its Senior Vice President, Global Regulatory Affairs pursuant to the terms of an Executive Employment Agreement with the Company dated May 16, 2016 (the “Prior Agreement”). Executive and the Company hereby agree to amend and restate the Prior Agreement. The terms and conditions set forth in this AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of the effective date of the first registration statement filed by the Company to register shares of its common stock for sale to the public through one or more underwriters (the “Effective Date”), and shall supersede and replace the terms and conditions set forth in the Prior Agreement. Certain capitalized terms used in this Agreement are defined in Section 6.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • April 18th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Jeremy Levin (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its Chief Executive Officer (“CEO”) pursuant to the terms of an Executive Employment Agreement with the Company dated June 5, 2015 (the “Prior Agreement”). Executive and the Company hereby agree to amend and restate the Prior Agreement. The terms and conditions set forth in this AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of the effective date of the first registration statement filed by the Company to register shares of its common stock for sale to the public through one or more underwriters (the “Effective Date”), and shall supersede and replace the terms and conditions set forth in the Prior Agreement. Certain capitalized terms used in this Agreement are defined in Section 6.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • April 18th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
Amit Rakhit (“Executive”) is currently employed by OVID THERAPEUTICS INC. (the “Company”) as its Chief Medical and Portfolio Management Officer pursuant to the terms of an Executive Employment Agreement with the Company dated December 6, 2015 (the “Prior Agreement”). Executive and the Company hereby agree to amend and restate the Prior Agreement. The terms and conditions set forth in this AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) shall become effective as of the effective date of the first registration statement filed by the Company to register shares of its common stock for sale to the public through one or more underwriters (the “Effective Date”), and shall supersede and replace the terms and conditions set forth in the Prior Agreement. Certain capitalized terms used in this Agreement are defined in Section 6.
